Emerald Bioscience is a biopharmaceutical company focused on the discovery, development and commercialization of new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2) located throughout multiple organ systems in the body. Currently, Emerald Bioscience is developing a novel and proprietary class of product candidates that are designed to improve therapeutic options based on chemical engineering that allow drug candidates to have enhanced bioavailability and more predictable pharmacokinetics, leading to optimized efficacy and safety.
To understand and leverage the science of cannabinoids to bring precision medicine to the treatment of a spectrum of diseases utilizing bioengineering in drug design.
To become the leading developer of regulatory-approved, cannabinoid-based therapeutics, utilizing world-class proprietary bioengineering coupled with innovative biosynthetic manufacturing. Our incubator model is designed to monetize our pharmaceuticalized cannabinoids during optimal stages of drug development to maximize shareholder value by addressing large-market, unmet medical needs on a global scale in a strategic, regulatory-validated and cost-effective manner.